US Patent

US10603281 — Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same

Method of Use · Assigned to Laboratorios Leon Farma SA · Expires 2031-06-28 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions and methods for administering active contraceptive drugs, specifically progestogen-only contraceptives like Drosphirenone.

USPTO Abstract

The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptive (âPOCâ), such as Drosphirenone.

Drugs covered by this patent

Slynd (DROSPIRENONE) · Exeltis Usa Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2553`	—	Slynd
`U-2553`	—	Slynd

Patent Metadata

Patent number: US10603281
Jurisdiction: US
Classification: Method of Use
Expires: 2031-06-28
Drug substance claim: No
Drug product claim: No
Assignee: Laboratorios Leon Farma SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.